How HIV treatment could result in effective prevention

Papers of special note have been highlighted as: ▪ of interest

Bibliography

• 1  Braitstein P, Brinkhof MW, Dabis F et al.; Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration; ART Cohort Collaboration (ART-CC) groups: Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet367(9513),817–824 (2006).
  MedlineGoogle Scholar
• 2  Palella F, Delaney KM, Moorman AC et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med.338,853–860 (1998).▪ Using national surveillance data from the USA, this paper documents marked reductions in morbidity and mortality caused by AIDS, which was attributable to increased use of antiretroviral therapy.
  MedlineGoogle Scholar
• 3  Bartlett J, Shao JF: Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. Lancet Infect. Dis.9(10),637–649 (2009).
  MedlineGoogle Scholar
• 4  Harrington M, Carpenter CC: Hit HIV-1 hard, but only when necessary. Lancet355(9221),2147–2152 (2000).
  Medline CASGoogle Scholar
• 5  Wilkin T, Gulick RM: When to start antiretroviral therapy? Clin. Infect. Dis.47(12),1580–1586 (2008).
  MedlineGoogle Scholar
• 6  Lane H, Neaton JD: When to start therapy for HIV infection: a swinging pendulum in search of data. Ann. Int. Med.138(8),680–681 (2003).
  MedlineGoogle Scholar
• 7  Granich R, Gilks CF, Dye C, De Cock KM, Williams BG: Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet373(9657),48–57 (2009).▪ Recent modeling study that used the HIV/AIDS epidemic in South Africa to explore the impact of testing all adults annually for HIV and starting individuals on highly active antiretroviral therapy (HAART) immediately after a positive HIV diagnosis. This theoretical strategy reported that HIV incidence and mortality could be reduced to less than one case per 1000 people within 10 years.
  MedlineGoogle Scholar
• 8  Dodd P, Garnett GP, Hallett TB: Examining the promise of HIV elimination by ‘test and treat’ in hyperendemic settings. AIDS24(5),729–735 (2010).
  MedlineGoogle Scholar
• 9  Quinn T: HIV epidemiology and the effects of antiviral therapy on long-term consequences. AIDS22(Suppl. 3),S7–S12 (2008).
  Medline CASGoogle Scholar
• 10  WHO: Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. WHO Press, Geneva, Switzerland (2009).
  Google Scholar
• 11  Montaner J, Hogg R, Wood E et al.: The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet368(9534),531–536 (2006).
  MedlineGoogle Scholar
• 12  Stephenson J: Scientists explore use of anti-HIV drugs as a means to slow HIV transmission. J. Am. Med. Assoc.303(18),1798–1799 (2010).
  CASGoogle Scholar
• 13  Cu-Uvin S, Caliendo AM, Reinert S et al.: Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS14(4),415–421 (2000).
  Medline CASGoogle Scholar
• 14  Vernazza P, Gilliam BL, Flepp M et al.: Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS11(10),1249–1254 (1997).
  Medline CASGoogle Scholar
• 15  Jackson J, Musoke P, Fleming T et al.: Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet362(9387),859–868 (2003).
  Medline CASGoogle Scholar
• 16  Karon J, Fleming PL, Steketee RW, De Cock KM: HIV in the United States at the turn of the century: an epidemic in transition. Am. J. Public Health91(7),1060–1068 (2001).
  Medline CASGoogle Scholar
• 17  Quinn TC MJ, Wawer N, Sewankambo D et al.: Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N. Engl. J. Med.342,921–929 (2000).▪ Study conducted in rural Uganda; plasma viral load was the chief predictor of the risk of heterosexual transmission of HIV, and transmission was rare among individuals with HIV RNA less than 1500 copies/ml.
  Medline CASGoogle Scholar
• 18  Tovanabutra S, Robison V, Wongtrakul J et al.: Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J. Acquir. Immune Defic. Syndr.29(3),275–283 (2002).
  MedlineGoogle Scholar
• 19  Musicco M, Lazzarin A, Nicolosi A et al.: Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. Arch. Intern. Med.154(17),1971–1976 (1994).
  Medline CASGoogle Scholar
• 20  Castilla J, Del Romero J, Hernando V, Marincovich B, García S, Rodríguez C: Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J. Acquir. Immune Defic. Syndr.40(1),96–101 (2005).▪ Conducted among heterosexual couples in Spain. Found that HAART was associated with an 80% reduction in HIV transmission irrespective of changes in other factors that affect transmission.
  MedlineGoogle Scholar
• 21  Donnell D, Kiarie J, Thomas K et al.: ART and risk of heterosexual HIV-1 transmission in HIV-1 serodiscordant African couples: a multinational prospective study. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA 16–19 February 2010.
  Google Scholar
• 22  Das-Douglas M, Chu P, Santos GM et al.: Decreases in community viral load are associated with a reduction in new HIV diagnoses in San Francisco. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA 16–19 February 2010.
  Google Scholar
• 23  Montaner J, Wood E, Kerr T et al.: Association of expanded HAART coverage with a decrease in new HIV diagnoses, particularly among injection drug users in british columbia, canada. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA 16–19 February 2010.
  Google Scholar
• 24  Cohen M, Gay C, Kashuba AD, Blower S, Paxton L: Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann. Int. Med.146(8),591–601 (2007).▪ Examines various options currently under study for using antiretrovirals to prevent HIV transmission, using pre- and post-exposure prophylaxis.
  MedlineGoogle Scholar
• 25  Parker R: Civil society, political mobilization, and the impact of HIV scale-up on health systems in Brazil. J. Acquir. Immune Defic. Syndr.52(Suppl. 1),S49–S51 (2009).
  MedlineGoogle Scholar
• 26  Ainsworth M, Beyrer C, Soucat A: AIDS and public policy: the lessons and challenges of “success” in Thailand. Health Policy64(1),13–37 (2001).
  Google Scholar
• 27  Fang C, Hsu HM, Twu SJ et al.; Division of AIDS and STD, Center for Disease Control, Department of Health, Executive Yuan: decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J. Infect. Dis.190(5),879–885 (2004).
  MedlineGoogle Scholar
• 28  Achmat Z, Simcock J: Combining prevention, treatment and care: lessons from South Africa. AIDS21(Suppl. 4),S11–S20 (2007).
  MedlineGoogle Scholar
• 29  Chopra M, Lawn JE, Sanders D et al.; Lancet South Africa team: achieving the health Millennium Development Goals for South Africa: challenges and priorities. Lancet374(9694),1023–1031 (2009).
  MedlineGoogle Scholar
• 30  Coovadia H, Jewkes R, Barron P, Sanders D, McIntyre D: The health and health system of South Africa: historical roots of current public health challenges. Lancet374(9692),817–834 (2009).
  MedlineGoogle Scholar
• 31  Bunnell R, Opio A, Musinguzi J et al.: HIV transmission risk behavior among HIV-infected adults in Uganda: results of a nationally representative survey. AIDS22(5),617–624 (2008).
  MedlineGoogle Scholar
• 32  Harries A, Schouten EJ, Libamba E: Scaling up antiretroviral treatment in resource-poor settings. Lancet367(9525),1870–1872 (2006).
  MedlineGoogle Scholar
• 33  El-Sadr W, Mayer KH, Hodder SL: AIDS in America – forgotten but not gone. N. Engl. J. Med.362(11),967–970 (2010).
  Medline CASGoogle Scholar
• 34  Pilcher C, Tien HC, Eron JJ Jr et al.; Quest Study; Duke-UNC-Emory Acute HIV Consortium: Brief but efficient: acute HIV infection and the sexual transmission of HIV. J. Infect. Dis.189(10),1785–1792 (2004).
  MedlineGoogle Scholar
• 35  Hirsch M: Initiating therapy: when to start, what to use. J. Infect. Dis.197(Suppl. 3),S252–S260 (2008).
  MedlineGoogle Scholar
• 36  Brenner B, Roger M, Routy JP et al.; Quebec Primary HIV Infection Study Group: High rates of forward transmission events after acute/early HIV-1 infection. J. Infect. Dis.195(7),951–959 (2007).
  Medline CASGoogle Scholar
• 37  Wawer M, Gray RH, Sewankambo NK et al.: Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J. Infect. Dis.191(9),1403–1409 (2005).
  MedlineGoogle Scholar
• 38  Streeck H, Jessen H, Alter G et al.: Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J. Infect. Dis.194(6),734–739 (2004).
  Google Scholar
• 39  Hecht F, Wang L, Collier A et al.; AIEDRP Network: A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J. Infect. Dis.194(6),725–733 (2006).
  MedlineGoogle Scholar
• 40  Abbas UL, Anderson RM, Mellors JW: Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings. J. Acquir. Immune Defic. Syndr.41(5),632–641 (2006).
  MedlineGoogle Scholar
• 41  Garnett G, Gazzard B: Risk of HIV transmission in discordant couples. Lancet372(9635),270–271 (2008).
  MedlineGoogle Scholar
• 42  Jahn A, Floyd S, Crampin AC et al.: Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet371(9624),1603–1611 (2008).
  MedlineGoogle Scholar
• 43  Walensky R, Wolf LL, Wood R et al.; CEPAC (Cost-Effectiveness of Preventing AIDS Complications)-International Investigators: When to start antiretroviral therapy in resource-limited settings. Ann. Int. Med.151(3),157–166 (2009).
  MedlineGoogle Scholar
• 44  Velasco-Hernandez J, Gershengorn HB, Blower SM: Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect. Dis.2(8),487–493 (2002).▪ Quantified the impact of HAART in reducing epidemic severity using mathematical models, suggesting that HAART could be an effective prevention tool even with high levels of drug resistance and risky sex, and could also be effective at eradicating a high-prevalence HIV epidemic.
  Medline CASGoogle Scholar
• 45  Lima VD, Johnston K, Hogg RS et al.: Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J. Infect. Dis.198(1),59–67 (2008).
  Medline CASGoogle Scholar
• 46  Kumarasamy N, Venkatesh KK, Cecelia AJ et al.: Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. AIDS Patient Care STDs22(4),337–344 (2008).
  Medline CASGoogle Scholar
• 47  Bender M, Kumarasamy N, Mayer KH et al.: Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin. Infect. Dis.50(3),416–425 (2010).
  MedlineGoogle Scholar
• 48  Hammer S, Eron JJ Jr, Reiss P et al.; International AIDS Society-USA: antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. J. Am. Med. Assoc.300(5),555–570 (2008).
  Medline CASGoogle Scholar
• 49  May M, Sterne JA, Sabin C et al.; Antiretroviral Therapy (ART) Cohort Collaboration: Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS21(9),1185–1197 (2007).
  MedlineGoogle Scholar
• 50  Lichtenstein K, Armon C, Buchacz K et al.; HIV Outpatient Study (HOPS) Investigators: Initiation of antiretroviral therapy at CD4 cell counts ≥350 cells/mm³ does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency. J. Acquir. Immune Defic. Syndr.47(1),27–35 (2008).
  MedlineGoogle Scholar
• 51  Kitahata M, Gange SJ, Abraham AG et al.; NA-ACCORD Investigators: Effect of early versus deferred antiretroviral therapy for HIV on survival. N. Engl. J. Med.360(18),1815–1826 (2009).▪ Observational study conducted in North America compared the relative risk of death for HIV-infected patients who initiated HAART at prespecified CD4 cut-offs, and found that promptly initiating therapy at higher CD4 cell counts improved survival.
  Medline CASGoogle Scholar
• 52  Moore R, Keruly JC: CD4⁺ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin. Infect. Dis.44(3),441–446 (2007).
  MedlineGoogle Scholar
• 53  Mocroft A, Phillips AN, Gatell J et al.; EuroSIDA Study Group: Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet370(9585),407–413 (2007).
  Medline CASGoogle Scholar
• 54  Gras L, Kesselring AM, Griffin JT et al.; ATHENA, Netherlands National Observational Cohort Study: CD4 cell counts of 800 cells/mm³ or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm³ or greater. J. Acquir. Immune Defic. Syndr.45(2),183–192 (2007).
  MedlineGoogle Scholar
• 55  Gilks C, Crowley S, Ekpini R et al.: The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet568(9534),505–510 (2006).
  Google Scholar
• 56  Libamba E, Makombe S, Harries AD et al.: Scaling up antiretroviral therapy in Africa: learning from tuberculosis control programmes – the case of Malawi. Int. J. Tuberc. Lung Dis.9(10),1062–1071 (2005).
  Medline CASGoogle Scholar
• 57  Lowrance D, Makombe S, Harries AD et al.: A public health approach to rapid scale-up of antiretroviral treatment in Malawi during 2004–2006. J. Acquir. Immune Defic. Syndr.49(3),287–293 (2008).
  MedlineGoogle Scholar
• 58  Van Damme W, Kober K, Laga M: The real challenges for scaling up ART in sub-Saharan Africa. AIDS20(5),653–656 (2006).
  MedlineGoogle Scholar
• 59  Bates I, Maitland K: Are laboratory services coming of age in sub-Saharan Africa? Clin. Infect. Dis.42(3),383–384 (2006).
  MedlineGoogle Scholar
• 60  Harries A, Makombe SD, Schouten EJ, Ben-Smith A, Jahn A: Different delivery models for antiretroviral therapy in sub-Saharan Africa in the context of ‘universal access’. Trans. R. Soc. Trop. Med. Hyg.102,310–311 (2008).
  MedlineGoogle Scholar
• 61  Reynolds S, Bartlett JG, Quinn TC, Beyrer C, Bollinger RC: Antiretroviral therapy where resources are limited. N. Engl. J. Med.348(18),1806–1809 (2003).
  MedlineGoogle Scholar
• 62  Harries A, Schouten EJ, Makombe SD et al.: Ensuring uninterrupted supplies of antiretroviral drugs in resource-poor settings: an example from Malawi. Bull. World Health Organ.85(2),152–155 (2007).
  MedlineGoogle Scholar
• 63  Cohen J: HIV/AIDS. The great funding surge. Science321(5888),512–519 (2008).
  Medline CASGoogle Scholar
• 64  Tassie J, Szumilin E, Calmy A, Goemaere E; Médecins Sans Frontières: Highly active antiretroviral therapy in resource-poor settings: the experience of Médecins Sans Frontières. AIDS17(13),1995–1997 (2003).
  MedlineGoogle Scholar
• 65  Anema A, Wood E, Montaner JS: The use of highly active retroviral therapy to reduce HIV incidence at the population level. CMAJ179(1),13–14 (2008).
  MedlineGoogle Scholar
• 66  McNeil D: At front lines, AIDS war is falling apart. The New York Times 10 May 2010.
  Google Scholar
• 67  McCoy D, Chopra M, Loewenson R et al.: Expanding access to antiretroviral therapy in sub-Saharan Africa: avoiding the pitfalls and dangers, capitalizing on the opportunities. Am. J. Public Health95(1),18–22 (2005).
  MedlineGoogle Scholar
• 68  Losina E, Yazdanpanah Y, Deuffic-Burban S et al.: The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d’Ivoire. Antiviral Ther.12(4),543–551 (2005).
  Google Scholar
• 69  Hosseinipour M, Cohen MS, Vernazza PL, Kashuba AD: Can antiretroviral therapy be used to prevent sexual transmission of human immunodeficiency virus type 1? Clin. Infect. Dis.34(10),1391–1395 (2002).
  MedlineGoogle Scholar
• 70  Goldie S, Yazdanpanah Y, Losina E et al.: Cost-effectiveness of HIV treatment in resource-poor settings – the case of Côte d’Ivoire. N. Engl. J. Med.355(11),1141–1153 (2006).▪ Assessed the cost–effectiveness of various treatment strategies, and found that a strategy that included opportunistic infection prophylaxis and HAART, with the use of clinical criteria or in combination with CD4 testing to guide timing of treatment, was an economically attractive investment in resource-limited settings.
  Medline CASGoogle Scholar
• 71  Freedberg K, Kumarasamy N, Losina E et al.: Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS21(4),S117–S128 (2007).
  MedlineGoogle Scholar
• 72  Freedberg K, Losina E, Weinstein MC et al.: The cost effectiveness of combination antiretroviral therapy for HIV disease. N. Engl. J. Med.344(11),824–831 (2001).
  Medline CASGoogle Scholar
• 73  Granich R, Kahn J, Bennett R et al.; the ART IMPACT Study Group: Economic analysis of ART for prevention of HIV transmission in a South African generalized HIV epidemic setting. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA 16–19 February 2010.
  Google Scholar
• 74  Ventelou B, Moatti JP, Videau Y, Kazatchkine M: ‘Time is costly’: modelling the macroeconomic impact of scaling-up antiretroviral treatment in sub-Saharan Africa. AIDS22(1),107–113 (2008).
  MedlineGoogle Scholar
• 75  Ivers L, Kendrick D, Doucette K: Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin. Infect. Dis.41,217–224 (2005).
  Medline CASGoogle Scholar
• 76  Mukadi Y, Maher D, Harries A: Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS15(2),143–152 (2001).
  Medline CASGoogle Scholar
• 77  Badri M, Wilson D, Wood R: Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet359(9323),2059–2064 (2002).
  MedlineGoogle Scholar
• 78  Fisher J, Smith L: Secondary prevention of HIV infection: the current state of prevention for positives. Curr. Opin. HIV AIDS4(4),279–287 (2009).
  MedlineGoogle Scholar
• 79  Hogben M, Liddon N: Disinhibition and risk compensation: scope, definitions, and perspective. Sex. Transm. Dis.35(12),1009–1010 (2008).
  MedlineGoogle Scholar
• 80  Katz M, Schwarcz SK, Kellogg TA et al.: Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am. J. Public Health92(3),388–394 (2002).
  MedlineGoogle Scholar
• 81  Bunnell R, Ekwaru JP, Solberg P et al.: Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS20(1),85–92 (2006).
  MedlineGoogle Scholar
• 82  Crepaz N, Hart TA, Marks G: Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. J. Am. Med. Assoc.292(2),224–236 (2004).▪ Meta-analysis of studies examining sexual risk behavior after initiating HAART conducted in the developed world suggested that HAART-experienced patients did not exhibit increased sexual risk behavior.
  Medline CASGoogle Scholar
• 83  Farmer P, Leandre F, Mukherjee JS et al.: Community-based approaches to HIV treatment in resource-poor settings. Lancet358(9279),404–409 (2001).
  Medline CASGoogle Scholar
• 84  Mills EJ, Nachega JB, Buchan I et al.: Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA296(6),679–690 (2006).▪ Meta-analysis of studies examining HAART adherence in sub-Saharan Africa and North America found that favorable levels of adherence, which can be assessed via patient self-report, could be achieved in sub-Saharan Africa.
  Medline CASGoogle Scholar
• 85  Oyugi J, Byakika-Tusiime J, Ragland K et al.: Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS21(8),965–971 (2007).
  Medline CASGoogle Scholar
• 86  Bangsberg DR: Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin. Infect. Dis.43(7),939–941 (2006).
  Medline CASGoogle Scholar
• 87  Paterson D, Swindells S, Mohr J et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Int. Med.133(1),21–30 (2000).
  Medline CASGoogle Scholar
• 88  Leigh Brown A, Frost SD, Mathews WC et al.: Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J. Infect. Dis.187(4),683–686 (2003).
  MedlineGoogle Scholar
• 89  Yerly S, Jost S, Telenti A et al.: Infrequent transmission of HIV-1 drug-resistant variants. Antivir. Ther.9(3),375–384 (2004).
  Medline CASGoogle Scholar
• 90  Margot N, Lu B, Cheng A, Miller MD; Study 903 Team: Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. HIV Med.7(7),442–450 (2006).
  Medline CASGoogle Scholar
• 91  Daar E, Richman DD: Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance. AIDS Res. Hum. Retroviruses21(5),343–357 (2005).
  Medline CASGoogle Scholar
• 92  Bennett D, Bertagnolio S, Sutherland D, Gilks CF: The World Health Organization’s global strategy for prevention and assessment of HIV drug resistance. Antiviral Ther.13(Suppl. 2),1–13 (2008).
  MedlineGoogle Scholar
• 93  Cardo D, Culver DH, Ciesielski CA et al.: A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N. Engl. J. Med.337(21),1485–1490 (1997).
  Medline CASGoogle Scholar
• 94  Baggaley R, Ferguson NM, Garnett GP: The epidemiological impact of antiretroviral use predicted by mathematical models: a review. Emerg. Themes Epidemiol.10(2),9 (2005).
  Google Scholar
• 95  De Cock K, Gilks CF, Lo YR, Guerma T: Can antiretroviral therapy eliminate HIV transmission? Lancet373(9657),7–9 (2009).
  MedlineGoogle Scholar
• 96  Walensky R, Paltiel AD, Losina E et al.: The survival benefits of AIDS treatment in the United States. J. Infect. Dis.194(1),11–19 (2006).
  MedlineGoogle Scholar
• 97  Vernazza P, Hirschel B, Bernasconi E, Flepp M: Les personnes seropositives ne souff rant d’aucune autre MST et suivant un traitment antiretroviral effi cie ne transmettent pas le VIH par voie sexuelle. Bull. Med. Suisses89,165–169 (2008).
  Google Scholar
• 98  Boyd M, Cooper DA: Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research. AIDS21(Suppl. 4),S55–S63 (2007).
  MedlineGoogle Scholar
• 99  Pujades-Rodríguez M, O’Brien D, Humblet P, Calmy A: Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières. AIDS22(11),1305–1312 (2008).
  Medline CASGoogle Scholar
• 100  Venkatesh K, Kumarasamy N, Mayer KH: Indian manufacture of new generic antiretrovirals: implications for global access to anti-HIV drugs. HIV Ther.4(1),1–4 (2010).
  Google Scholar
• 201  2008 update on the global AIDS epidemic. www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_Global_report.asp.
  Google Scholar
• 202  Health Prevention Trials Network. 2007. www.hptn.org/research_studies/hptn052.asp.
  Google Scholar